









Markets
/
Stocks
/
nasdaq-glue
/

Monte Rosa Therapeutics Inc

GLUE

6.930USD

+0.570+8.96%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

427.70MMarket Cap

17.70P/E TTM



Monte Rosa Therapeutics Inc

6.930

+0.570+8.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

13 / 506

Overall Ranking

78 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

16.714

Target Price

+162.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.62M.

Fairly Valued

The company’s latest PE is 17.98, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 62.74M shares, decreasing 3.77% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 6.23M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 8.27, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 23.19M, representing a year-over-year increase of 394.01%, while its net profit experienced a year-over-year increase of 59.44%.

Score

Industry at a Glance

Previous score

8.27

Change



Financials

7.74

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.96

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 3.40, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 16.51, which is 125.44% below the recent high of 37.21 and 21.53% above the recent low of 12.95.

Score

Industry at a Glance

Previous score

3.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Monte Rosa Therapeutics Inc is 17.00, with a high of 20.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

16.714

Target Price

+162.80%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Monte Rosa Therapeutics Inc

GLUE

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 8.89, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 7.77 and the support level at 4.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.89

Change

0.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MACD(12,26,9)

0.471

Buy

RSI(14)

72.728

Buy

STOCH(KDJ)(9,3,3)

70.927

Buy

ATR(14)

0.497

High Vlolatility

CCI(14)

125.890

Buy

Williams %R

17.958

Overbought

TRIX(12,20)

0.945

Sell

StochRSI(14)

75.430

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.300

Buy

MA10

5.576

Buy

MA20

5.173

Buy

MA50

5.097

Buy

MA100

4.811

Buy

MA200

5.542

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 101.99%, representing a quarter-over-quarter increase of 3.14%. The largest institutional shareholder is PRFDX, holding a total of 6.23M shares, representing 10.09% of shares outstanding, with 11.82% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

7.69M

T. Rowe Price Associates, Inc.

Star Investors

6.56M

-6.76%

BVF Partners L.P.

5.66M

+28.84%

Versant Ventures

5.65M

Baker Bros. Advisors LP

4.92M

Avoro Capital Advisors LLC

4.65M

+6.92%

Suvretta Capital Management, LLC

3.36M

+114.86%

BlackRock Institutional Trust Company, N.A.

3.22M

-2.24%

The Vanguard Group, Inc.

Star Investors

3.10M

-1.78%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.